Table of Content



List of Tables
List of Figures
Introduction
Global Markets Direct Report Coverage
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Overview
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Development
Products under Development by Stage of Development
Products under Development by Therapy Area
Products under Development by Indication
Products under Development by Companies
Products under Development by Universities/Institutes
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Therapeutics Assessment
Assessment by Mechanism of Action
Assessment by Route of Administration
Assessment by Molecule Type
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Companies Involved in Therapeutics Development
CymaBay Therapeutics Inc
Dong-A Socio Holdings Co Ltd
Hyundai Pharma Co Ltd
Japan Tobacco Inc
Mankind Pharma Ltd
Merck & Co Inc
Scohia Pharma Inc
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Drug Profiles
DA-1241 - Drug Profile
Product Description
Mechanism Of Action
History of Events
HOB-047 - Drug Profile
Product Description
Mechanism Of Action
JTP-109192 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MBX-2982 - Drug Profile
Product Description
Mechanism Of Action
History of Events
MKP-10241 - Drug Profile
Product Description
Mechanism Of Action
SCO-094 - Drug Profile
Product Description
Mechanism Of Action
History of Events
Small Molecule to Agonize GRP119 for Type 2 Diabetes and Obesity - Drug Profile
Product Description
Mechanism Of Action
Small Molecules to Agonize GPR119 for Type 2 Diabetes - Drug Profile
Product Description
Mechanism Of Action
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Dormant Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Discontinued Products
Glucose Dependent Insulinotropic Receptor (G Protein Coupled Receptor 119 or GPR119) - Product Development Milestones
Featured News & Press Releases
Apr 14, 2021: Mankind Pharma seeks approval from CDSCO for treatment of type 2 diabetes, new drug will come in the market
Feb 08, 2021: First-in-class GPR119 agonist of Dong-A ST, DA-1241 improved glucose control in patients with type 2 diabetes in US phase 1b study
Nov 05, 2020: CymaBay announces study to evaluate the potential for GPR119 agonists to prevent hypoglycemia in type 1 diabetes
Aug 11, 2020: SCOHIA initiates a phase 1 study on a dual GLP-1 and GIP receptor agonist (SCO-094)
May 10, 2020: Hyundai Pharm’s diabetes drug gets FDA approval for phase 2 clinical trial
Nov 05, 2009: Metabolex Closes $8.6 Million Fincing Round
Nov 12, 2008: Metabolex Announces Positive Results From Phase 1a Clinical Trial Of MBX-2982
Mar 26, 2008: Metabolex, Inc. Initiates Phase 1 Trial Of MBX-2982
Appendix
Methodology
Coverage
Secondary Research
Primary Research
Expert Panel Validation
Contact Us
Disclaimer



List of Figures


List of Figures
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Top 10 Indications, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Routes of Administration, 2022
Number of Products by Stage and Routes of Administration, 2022
Number of Products by Molecule Types, 2022
Number of Products by Stage and Molecule Types, 2022

List of Tables


List of Tables
Number of Products under Development by Stage of Development, 2022
Number of Products under Development by Therapy Areas, 2022
Number of Products under Development by Indication, 2022
Number of Products under Development by Companies, 2022
Products under Development by Companies, 2022
Number of Products under Investigation by Universities/Institutes, 2022
Products under Investigation by Universities/Institutes, 2022
Number of Products by Stage and Mechanism of Actions, 2022
Number of Products by Stage and Route of Administration, 2022
Number of Products by Stage and Molecule Type, 2022
Pipeline by CymaBay Therapeutics Inc, 2022
Pipeline by Dong-A Socio Holdings Co Ltd, 2022
Pipeline by Hyundai Pharma Co Ltd, 2022
Pipeline by Japan Tobacco Inc, 2022
Pipeline by Mankind Pharma Ltd, 2022
Pipeline by Merck & Co Inc, 2022
Pipeline by Scohia Pharma Inc, 2022
Dormant Products, 2022
Dormant Products, 2022 (Contd..1)
Discontinued Products, 2022